The study uses the Soberana 01 vaccine candidate, the first to receive authorization in Cuba for tests on human beings, and seeks to “stimulate protective levels of neutralizing antibodies against possible reinfection.”
by OnCuba Staff January 26, 2021 in Cuba
Cuba is carrying out a clinical trial in people convalescing from COVID-19, who had a minor clinical picture or were asymptomatic, the official media reported.
The study uses the Soberana 01 vaccine candidate, the first to receive authorization in Cuba for tests on human beings, and seeks to “stimulate protective levels of neutralizing antibodies against possible reinfection,” Prensa Latina (PL) agency reported.
The agency recalled that “globally there are cases of people infected with this coronavirus who were reinfected, even with much more acute and serious forms of the disease,” which is why the trial that is taking place on the island “also seeks to protect this risk group.”
The test began on January 9 at the Institute of Hematology and Immunology and involves 30 volunteers, aged 19 to 59, “who were in contact with the virus and currently have a negative PCR.” These people received a single dose of the vaccine on day 16 and “from that moment on, they are being closely monitored through doctor’s offices and direct contact with the researchers.”
Dr. Rolando Ochoa, a specialist in Immunology at the Finlay Vaccine Institute, explained that the formulation of Soberana 01 used in the test “is simpler and safer, according to the characteristics of the population group under study.”